Double Transgenic APPxPS1 Mouse Models – APP[V717I]xPS1[A246E] mouse model

Both the APP[V717I]xPS1[A246E] mouse model and the APP[V717I] mouse model are widely used in preclinical Alzheimer’s disease research and help you generate comparable preclinical efficacy readouts, including amyloid-β (Aβ) accumulation, plaque pathology, and downstream functional impairments. However, the key difference lies in disease kinetics and amyloid burden.  

The double transgenic APP×PS1 model was developed as a more aggressive complement to the late-onset APP single transgenic line featuring the “London” mutation ([V717I]), associated with early onset of Alzheimer’s disease (Dewachter et al., 2000). This familial Alzheimer’s disease mutation increases total Aβ production and shifts processing toward the more aggregation-prone Aβ42 species, thereby promoting amyloid plaque formation in an age-dependent manner. 

However, by introducing the human PS1[A246E] mutation in addition to APP[V717I], the resulting combined model features a more aggressive and accelerated amyloid pathology phenotype (Dewachter et al., 2000). The PS1[A246E] mutation is a clinically identified early-onset familial Alzheimer’s disease mutation located in the transmembrane domain of presenilin-1, a key component of the γ-secretase complex. Expression of mutant PS1 under the murine Thy-1 promoter further enhances γ-secretase–mediated cleavage toward Aβ42 production. As a result, the double transgenic mice show a marked increase in brain Aβ42 levels and a dramatic elevation of the Aβ42/Aβ40 ratio compared to APP single transgenic mice (Dewachter et al., 2000), translating into accelerated amyloid pathology. 

While APP[V717I] mice develop plaques typically around 10 months of age, APP[V717I]×PS1[A246E] mice exhibit robust plaque deposition as early as 6 months. Plaques in the double transgenic model are predominantly Aβ42-rich, reflecting the strong biochemical impact of the PS1 mutation, compared to single APP mice which show increase in brain Aβ40 at 15 months of age.  

Therefore, from a practical perspective, the APPxPS1 model provides you with a shorter and more aggressive amyloid timeline, enabling faster evaluation of amyloid-lowering therapies, disease-modifying strategies, and cognition-related endpoints. The APP[V717I] single transgenic model, in contrast, may be preferred when studying slower, age-dependent amyloid progression.  

Read more about the APP[V717I] model and how it can be used in the evaluation of preclinical efficacy of your therapeutics targeting Alzheimer’s disease here.

In InnoSer’s APP[V717I]xPS1[A246E] mouse model, total amyloid-beta plaque and dense-core plaques (Thioflavin S+) accumulation in the subiculum can be detected from approximately 6 months of age with high levels of amyloid burden visible at 12 months of age, during which robust amyloid pathology is observed. Similarly, robust cortical Aβ40 and Aβ42 deposition is observed from 6 to 12 months of age and beyond.  

In this mouse model, the amyloid pathology is accompanied by age-dependent neuroinflammation, including astrocytosis (GFAP) and microgliosis (CD45), as well as elevated levels of the neuronal injury biomarker neurofilament light (NfL) in CSF and plasma from around 9 months of age. 

Contact our scientific team to access full longitudinal phenotyping datasets of the APPxPS1 mouse model.

While APPxPS1 mice develop robust amyloid pathology and dystrophic neurites containing hyperphosphorylated murine tau, they do not recapitulate full neurofibrillary tangle pathology. 

This absence of overt tangle pathology is consistent with other APP/PS1 transgenic mouse models. Amyloid-only models robustly reproduce cerebral beta amyloidosis but do not recapitulate the full spectrum of Alzheimer’s disease encompassing tau pathology. To model both amyloid plaques and neurofibrillary tangles in vivo, the incorporation of mutant human tau is required. 

Therefore, for therapies targeting combined amyloid-and-tau disease modification, we recommend the APP[V717I]xTau[P301S] mouse model, which recapitulates both extracellular amyloid plaques and progressive tau pathology, providing a more complete Alzheimer’s disease phenotype. 

Learn more about InnoSer’s combined amyloid and tau mouse model here.

Yes, APPxPS1 mice demonstrate robust impairments in spatial reference memory in the Morris Water Maze (MWM) task. During acquisition training, transgenic animals show delayed learning compared to controls. In probe trials, the transgenic APPxPS1 mice show significantly reduced spatial reference memory compared to non-transgenic controls (see also figures 1 and 2 of Easton et al., 2013). 

As an alternative in the APPxPS1 model, synaptic and memory-related deficits can be evaluated using electrophysiological readouts using ex vivo brain slices, such as hippocampal long-term potentiation (LTP), which provide sensitive measures of synaptic plasticity that can serve as a proxy measure for memory deficits in APPxPS1 mice. Indeed, APPxPS1 mice exhibit reduced potentiation response compared to wild-type mice ex vivo (click here to view the data).  

For programs where cognitive improvement is a primary endpoint, InnoSer’s APP[V717I]xPS1[A246E] mouse model may offer greater sensitivity, as this model demonstrates clear spatial memory deficits in the Morris water maze along with documented compound-mediated rescue effects (see also figures 1 and 2 of Easton et al., 2013).  

Reach out to InnoSer’s study experts to discuss including cognitive readouts in your preclinical efficacy study now.

Yes, published research has shown that disease modification has been demonstrated in the APP[V717I] mouse model in preclinical studies evaluating the efficacy of acetylcholinesterase inhibitors (Easton et al., 2013), GLP-1 receptor agonist (Hansen et al., 2016) and anti-PD1 antibodies (Latta-Mahieu et al., 2017).  

Data from a study (Easton et al., 2013) has shown a significant improvement in reference memory in APPxPS1 mice along with a dose-dependent reduction in brain Aβ. These results suggest that donepezil may alleviate cognitive impairments in Alzheimer’s disease, in part, by reducing brain Aβ.

Yes, at ≥8 months of age, APPxPS1 mice exhibit CAA, marked by deposition of Aβ in vessel walls. This vascular amyloid accumulation leads to progressive vessel wall damage, aneurysm formation, and ultimately cerebral microbleeds by 12–15 months, mirroring vascular amyloidosis observed in a subset of AD patients.  

Additionally, pyroglutamate-modified Aβ₃(pE)-42, a pathogenic and aggregation-prone Aβ species found abundantly in human AD plaques, is detected in the insoluble brain fraction of APPxPS1 mice from 7 months onward. 

Cerebral amyloid angiopathy (CAA) is a common and clinically relevant cerebrovascular pathology characterized by the accumulation of Aβ peptides within the walls of cerebral blood vessels. CAA is present in a substantial proportion of Alzheimer’s disease (AD) patients and is increasingly recognized as a key contributor to vascular dysfunction, impaired cerebral blood flow, blood–brain barrier disruption, and intracerebral haemorrhage.  

In recent years, interest in CAA has grown markedly as clinical trial outcomes have highlighted vascular amyloid as a potential driver of treatment-related adverse events, including amyloid-related imaging abnormalities (ARIA). Consequently, CAA has emerged as an important target for mechanistic studies and for the preclinical evaluation of anti-amyloid therapies, particularly immunotherapies and approaches aimed at improving vascular amyloid clearance. 

Reach out to our team to explore how InnoSer can support the preclinical assessment of cerebral amyloid angiopathy (CAA) and amyloid-related imaging abnormalities (ARIA).

Yes, as a preclinical neurodegeneration CRO, InnoSer maintains access to established breeding cohorts of the APPxPS1 mouse model, enabling rapid study initiation depending on the required animal age and genotype.  

Our proactive colony planning ensures that your preclinical efficacy studies can be launched with minimal lead time.  

Contact our team to confirm current availability and obtain study timelines for your amyloid-lowering therapeutic still today.